Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients. Issue 4 (25th January 2022)

• Record Type: Journal Article
• Authors: Fan, Xinghua; Zhang, Hong; Wen, Zhipeng; Zheng, Xiaoli; Yang, Yi; Yang, Jihong
• Is Part Of: Pharmaocogenetics and genomics. Volume 32:Issue 4(2022)
• Page Start: 152
• Page End: 158
• Publication Date: 2022-01-25
• Subjects: CYP2C19 -- CYP2C9 -- CYP3A4 -- gene polymorphism -- pediatrics -- plasma concentration -- voriconazole; Pharmacogenetics -- Periodicals; Pharmacogenomics -- Periodicals; Genetic toxicology -- Periodicals; Biomedical genetics -- Periodicals; 615.7
• DOI: 10.1097/FPC.0000000000000464
• Languages: English
• ISSNs: 1744-6872

Abstract

Abstract : Objectives: Voriconazole is the most commonly used antifungal agent in clinical application. Previous studies suggested that voriconazole was extensively metabolized by CYP450 enzyme system, including CYP2C19, CYP2C9 and CYP3A4, which contributed to the individual variability of the pharmacokinetic process of voriconazole. This study aimed to investigate the effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole concentrations in Chinese pediatric patients. Methods: This study prospectively evaluated pediatric patients administrating voriconazole for the treatment or prophylaxis of invasive fungal infections from October 2018 to July 2020. Seven single-nucleotide polymorphisms in CYP2C19 ( CYP2C19*2, CYP2C19*3, and CYP2C19*17 ), CYP2C9 ( CYP2C9*3, CYP2C9*13 ) and CYP3A4 ( CYP3A4*22, rs4646437) were detected by real-time fluorescent PCR with TaqMan probes. The voriconazole trough plasma concentration was determined by UPLC-MS/MS. Results: A total of 68 pediatric patients were enrolled in this study. Our results showed that voriconazole plasma concentrations of patients with CYP2C19*2 or CYP2C19*3 allele were significantly higher than that with wild-type carriers ( P < 0.0001, P = 0.004, respectively). However, CYP2C9*3 and CYP3A4 rs4646437 were not significantly associated with voriconazole plasma levels. The CYP2C19*17, CYP2C9*13 and CYP3A4*22 alleles were not observed in our study. Additionally, multiple linear regression analysis indicated that CYP2C19*2 and CYP2C19*3 alleles remained predictors of voriconazole plasma concentration ( r 2 = 0.428; P < 0.0001). For CYP2C19 metabolizer phenotype, trough concentration of voriconazole was significantly lower in NM group compared with IM ( P < 0.0001) and PM ( P = 0.004) groups. Conclusion: Voriconazole plasma levels in pediatric patients are mainly affected by CYP2C19 gene polymorphisms.